Here we show compound CML-07–119, a selective inhibitor of GGPP synthase (GGPPS), to display an EC50 potency in the nanomolar range and to induce targeted cell death in several AML cell lines, including those harbouring TP53 mutations. Here, GGPS1 is linked to acute myeloid leukemia.